Strs Ohio Has $1.38 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Strs Ohio grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,501 shares of the company’s stock after purchasing an additional 189 shares during the period. Strs Ohio’s holdings in Medpace were worth $1,379,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of MEDP. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Medpace by 51,600.0% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,170 shares of the company’s stock valued at $1,606,000 after acquiring an additional 5,160 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Medpace by 71.3% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,056 shares of the company’s stock valued at $630,000 after acquiring an additional 856 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of Medpace during the 4th quarter valued at about $1,992,000. Cerity Partners LLC boosted its position in shares of Medpace by 8.3% during the 4th quarter. Cerity Partners LLC now owns 2,463 shares of the company’s stock valued at $755,000 after acquiring an additional 189 shares in the last quarter. Finally, Custom Index Systems LLC acquired a new stake in shares of Medpace during the 4th quarter valued at about $484,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MEDP. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Robert W. Baird lifted their price target on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 23rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Moderate Buy” and a consensus price target of $382.00.

Medpace Stock Up 1.1 %

Shares of MEDP stock opened at $376.26 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $187.03 and a 12-month high of $419.42. The company has a market capitalization of $11.66 billion, a P/E ratio of 42.37, a P/E/G ratio of 1.97 and a beta of 1.38. The firm has a 50-day moving average price of $396.82 and a 200 day moving average price of $322.00.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. During the same period in the previous year, the firm posted $2.12 earnings per share. The company’s revenue was up 26.5% on a year-over-year basis. As a group, research analysts expect that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Insiders Place Their Bets

In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now directly owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the completion of the sale, the insider now directly owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 189,340 shares of company stock valued at $76,651,647. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.